Mercer actuary David Knox says the data used to determine the old age dependency ratio is “totally out of date” and overstates the severity of the problem.
From their inception, SMSFs have always attracted more than their fair share of criticism. Now it’s an ageing membership that’s being used to restrict their numbers.
Seven ASX shares with Monster updates
An army of ASX shares has been updating the market today with their first-half results for FY22.
Here are the seven I like the look of and are on my watch list.
Keep up to date with the February 2022 reporting season calendar.
1. EML Payments Ltd (ASX: EML)
The EML share price has fallen 8.61% despite announcing revenue growth of 20%.
Although what likely caught the market’s eye is the earnings results, which fell 4% to $26.9 million.
EML’s cash flow also plunged 58% due to the timing of two customer receipts.
Positively, the business reaffirmed its guidance underlying EBITDA guidance of $58.0 to $65.0 million.
2. Nearmap Ltd (ASX: NEA)
The Nearmap share price increased 14% today before receding to a 5% gain after announcing a 28% rise in its annual contract value (ACV).
However, this ASX share remains loss-making, recording a cash outflow of $13.6 million for the half.
Management confirmed its FY22 guidance, saying that ACV would be at the upper bound of the $150 million to $160 million range.
3. Netwealth Group Ltd (ASX: NWL)
The Netwealth share price has plunged 15% after expense growth exceeded revenue in the first half.
Subsequently, profit for the period decreased marginally, to $27.6 million.
Positively it retained its title as the number one wealth platform in Australia reflecting its dominant market positioning.
4. Pro Medicus Limited (ASX: PME)
ASX shares have been moving in all directions today. The Pro Medicus share price is no exception, up 8.57% to $50.30.
Revenue is up 40.3%, underlying profit soared 53.5% and dividends increased 42.9%.
The business announced several key contract wins over the month including a seven-year $40 million contract with Novant Health.
“There were two key drivers behind the result. Firstly, the jump in transaction revenue from our US contracts… such as Northwestern, NYU and Medstar. Secondly, the extension of the German government contract to a fourth hospital”
5. SiteMinder Limited (ASX: SDR)
Recent ASX shares IPO SiteMinder provided its maiden reports to public investors, achieving revenue uplift of 9%.
Much of the result had been pre-released in January, hence the muted share price response today.
Positively, management expects with the resumption of global travel, the business to return to historical growth rates of 31% per annum.
6. Breville Group Ltd (ASX: BRG)
For a business that sells fancy kettles, it’s astonishing how profitable Breville is.
Revenue increased by 23.6% to $878 million while profit improved 25.1% to $77.7 million.
Gross margins were impacted by freight and product input costs. But this was offset by higher prices and lower promotional activities.
FY22 earnings is expected to be $156 million, in line with market expectations.
7. Corporate Travel Management Ltd (ASX: CTD)
ASX shares have been impacted by the pandemic in various ways, particularly travel.
Nonetheless, Corporate Travel has managed to improve its earnings to $18.2 million, up from a loss of $15.2 million in proper corresponding half.
Once borders reopen management estimates it will be the fourth biggest global corporate travel manager.
“[management expects] revenue of $810m and underlying EBITDA of $265m estimated on a full recovery”
Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.
